Venus Concept Inc. (NASDAQ:VERO) Sees Significant Drop in Short Interest

Venus Concept Inc. (NASDAQ:VERO) was the recipient of a large decline in short interest in January. As of January 30th, there was short interest totaling 72,826 shares, a decline of 57.8% from the January 15th total of 172,610 shares. Approximately 7.1% of the shares of the company are short sold. Based on an average daily volume of 32,768,333 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 32,768,333 shares, the days-to-cover ratio is currently 0.0 days. Approximately 7.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Venus Concept in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Venus Concept presently has an average rating of “Sell”.

Venus Concept Stock Performance

NASDAQ:VERO opened at $0.41 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.59 and a current ratio of 0.90. The company has a fifty day moving average of $1.85 and a two-hundred day moving average of $2.10. The stock has a market capitalization of $578,571.20, a PE ratio of -0.01 and a beta of -0.01. Venus Concept has a fifty-two week low of $0.35 and a fifty-two week high of $14.50.

Venus Concept (NASDAQ:VERO) last announced its earnings results on Thursday, November 13th. The company reported ($12.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.61) by ($8.53). Venus Concept had a negative net margin of 92.76% and a negative return on equity of 1,904.25%. The company had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.48 million.

Venus Concept Company Profile

Venus Concept Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.

Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation.